<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127855</url>
  </required_header>
  <id_info>
    <org_study_id>792014/001</org_study_id>
    <secondary_id>792014/002</secondary_id>
    <nct_id>NCT00127855</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine</brief_title>
  <official_title>A Phase II, Open (Partially Double-blind), Randomised, Controlled, Multicentre, Primary Vaccination Study to Evaluate the Immunogenicity (Including Immune Memory), Reactogenicity and Safety of Three Different Formulations of the GSK Biologicals' Combined Haemophilus Influenzae Type B-meningococcal Serogroups CY Conjugate Vaccine Given Concomitantly With Infanrix® Penta and Prevenar®, Versus ActHIB® and Meningitec® Given Concomitantly With Infanrix® Penta and Versus ActHIB® Given Concomitantly With Infanrix® Penta and Prevenar® in Infants According to a 2-4-6 Month Schedule.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study evaluated the safety and immunogenicity of 3 formulations of Hib-MenCY-TT vaccine
      compared to 2 control groups receiving licensed meningococcal serogroup C conjugate vaccine
      and/or licensed Hib conjugate vaccine administered at 2, 4, and 6 months of age. Antibody
      persistence and immune responses to polysaccharide vaccine boosters were additionally
      assessed at 11 to 14 months of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 1 Milligram Per Milliliter</measure>
    <time_frame>One month after primary vaccination (Month 5)</time_frame>
    <description>The cut-off concentration assessed was 1 milligram per milliliter (mg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup C (MenC) Titers Greater Than or Equal to 1:8</measure>
    <time_frame>One month after primary vaccination (Month 5)</time_frame>
    <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup Y (MenY) Titers Greater Than or Equal to 1:8</measure>
    <time_frame>One month after primary vaccination (Month 5)</time_frame>
    <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup C (MenC) Titers Greater Than or Equal to 1:8</measure>
    <time_frame>Prior to vaccination (Day 0), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup C (MenC) Titers</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs) expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With rSBA-MenY Titers Greater Than or Equal to 1:8</measure>
    <time_frame>Prior to vaccination (Day 0), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup Y (MenY) Titers</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>Titers were presented as geometric mean titers (GMTs) expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-polysaccharide C (PSC) Antibody Concentration Greater Than or Equal to 30 Micrograms Per Milliliter (µg/mL)</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>The cut-off concentration assessed was 30 micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-polysaccharide C (PSC) Antibody Concentration</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>Titers are presented as Geometric Mean Titers (GMTs) expressed as micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-polysaccharide Y (PSY) Antibody Concentration Greater Than or Equal to 30 Micrograms Per Milliliter (µg/mL)</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>The cut-off concentration assessed was 30 micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-polysaccharide Y (PSY) Antibody Concentration</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>Titers are presented as Geometric Mean Titers (GMTs) expressed as micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-PRP Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>The cut-off concentrations assessed were 0.15 micrograms per milliliter (µg/mL) and 1 µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP Antibody Concentration</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>Concentrations are presented as GMCs and expressed as µg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for Anti-diphtheria Antibodies</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Seroprotection is defined as anti-diphtheria toxoid antibody concentration greater than or equal to 0.1 International Units per Milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-diphtheria Antibody Concentrations</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Concentrations are presented as GMCs and expressed as International Units per Milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for Anti-tetanus Antibodies</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Seroprotection is defined as anti-tetanus toxoid antibody concentration greater than or equal to 0.1 International Units per Milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tetanus Antibody Concentrations</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Concentrations are presented as GMCs and expressed as International Units per Milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroseropositive for Anti-filamentus Haemagglutinin (FHA) Antibodies</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Seropositivity is defined as anti-FHA antibody concentration greater than or equal to 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti- FHA Antibody Concentrations</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Concentrations are presented as GMCs and expressed as Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroseropositive for Anti-pertactin (PRN) Antibodies</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Seropositivity is defined as anti-PRN antibody concentration greater than or equal to 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRN Antibody Concentrations</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Concentrations are presented as GMCs and expressed as Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroseropositive for Anti-pertussis Toxoid (PT) Antibodies</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Seropositivity is defined as anti-PT antibody concentration greater than or equal to 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti- PT Antibody Concentrations</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Concentrations are presented as GMCs and expressed as Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for Anti-hepatitis B (HBs) Antibodies</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Seroprotection is defined as anti-HBs antibody concentration greater than or equal to 10 Milli-International Units per Milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti- HBs Antibody Concentrations</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Concentrations are presented as GMCs and expressed as Milli-International Units per Milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for Anti-poliovirus Types 1, 2 and 3 Antibodies</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Seroprotection is defined as anti-polio antibody titer greater than or equal to 1:8 dilution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-poliovirus Types 1, 2 and 3 Antibody Titers</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Titers are presented as GMTs and expressed in terms of the 50 % inhibitory dilution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-pneumococcal Antibody Concentrations Greater Than or Equal to Pre-defined Cut-off Values</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Pneumococcal antibodies assessed included anti-4, anti-6B, anti-9V, anti-14, anti-18C, anti-19F and anti-23F antibodies. The cut-off values assessed were 0.05 and 0.2 micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-pneumococcal Antibody Concentrations</measure>
    <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
    <description>Pneumococcal antibodies assessed included anti-4, anti-6B, anti-9V, anti-14, anti-18C, anti-19F and anti-23F antibodies. Concentrations are presented as GMCs and expressed as micrograms per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms During the Primary Vaccination Course</measure>
    <time_frame>During the 8-Day (Day 0-7) follow-up period after any vaccine dose during the primary vaccination course</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, irritability, loss of appetite and fever (rectal temperature greater than or equal to 38 degrees Celcius).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms After Administration of the Polysaccharide Challenge Dose</measure>
    <time_frame>During the 8-Day (Day 0-7) follow-up period after the polysaccharide challenge dose</time_frame>
    <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, irritability, loss of appetite and fever (rectal temperature greater than or equal to 38 degrees Celcius).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events During the Primary Vaccination Course</measure>
    <time_frame>During the 31-Day (Day 0-30) follow-up period after any vaccine dose during the primary vaccination course</time_frame>
    <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Administration of the Polysaccharide Challenge Dose</measure>
    <time_frame>During the 31-Day (Day 0-30) follow-up period after administration of the polysaccharide challenge dose</time_frame>
    <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events During the Primary Vaccination Course</measure>
    <time_frame>Up to one month after the 3-dose primary vaccination course (Month 5)</time_frame>
    <description>Serious adverse events cover all medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events After Administration of the Polysaccharide Challenge Dose</measure>
    <time_frame>Up to one month following administration of the polysaccharide challenge dose (Month 11)</time_frame>
    <description>Serious adverse events cover all medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Haemophilus Influenzae Type b</condition>
  <condition>Neisseria Meningitidis</condition>
  <arm_group>
    <arm_group_label>MenHibrix Formulation 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenHibrix Formulation 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenHibrix Formulation 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menjugate Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ActHIB Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib-MenCY-TT vaccine (MenHibrix)</intervention_name>
    <description>Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively</description>
    <arm_group_label>MenHibrix Formulation 2 Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 3 Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 1 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningitec®</intervention_name>
    <description>Three doses were administered IM in right lower thigh at Months 0,2 and 4.</description>
    <arm_group_label>Menjugate Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ActHIB®</intervention_name>
    <description>Three doses were administered IM in left thigh at Months 0,2 and 4.</description>
    <arm_group_label>ActHIB Group</arm_group_label>
    <arm_group_label>Menjugate Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix® Penta</intervention_name>
    <description>Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.</description>
    <arm_group_label>ActHIB Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 2 Group</arm_group_label>
    <arm_group_label>Menjugate Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 3 Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 1 Group</arm_group_label>
    <other_name>DTPa-HBV-IPV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar®</intervention_name>
    <description>Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.</description>
    <arm_group_label>ActHIB Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 2 Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 3 Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 1 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mencevax® ACWY</intervention_name>
    <description>One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.</description>
    <arm_group_label>ActHIB Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 2 Group</arm_group_label>
    <arm_group_label>Menjugate Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 3 Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 1 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP (Polyribosyl Ribitol Phosphate)</intervention_name>
    <description>One dose was administered IM in deltoid region of left arm at Month 10 as booster.</description>
    <arm_group_label>ActHIB Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 2 Group</arm_group_label>
    <arm_group_label>Menjugate Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 3 Group</arm_group_label>
    <arm_group_label>MenHibrix Formulation 1 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  A male or female between, and including, 6 and 12 weeks (42-90 days) of age at the
             time of the first vaccination.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Vaccinated against hepatitis B at birth.

          -  Born after a gestation period of 36 - 42 weeks.

        Exclusion criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use
             during the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs since
             birth

          -  Any chronic drug therapy to be continued during the study period.

          -  Planned administration/ administration of a vaccine not foreseen by the study protocol
             within one month of the first dose of vaccine(s).

          -  Previous vaccination against diphtheria, tetanus, pertussis, polio, N. meningitidis of
             serogroups C and Y, Haemophilus influenzae type b or Streptococcus pneumoniae.

          -  History of or known exposure to diphtheria, tetanus, pertussis, polio, or invasive
             diseases due to N. meningitidis of serogroups C and Y, Haemophilus influenzae type b
             or Streptococcus pneumoniae.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6018</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Bryant KA, Marshall GS. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines. 2011 Jul;10(7):941-50. doi: 10.1586/erv.11.90. Review.</citation>
    <PMID>21806393</PMID>
  </reference>
  <reference>
    <citation>Nolan T, Lambert S, Roberton D, Marshall H, Richmond P, Streeton C, Poolman J, Boutriau D. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine. 2007 Dec 12;25(51):8487-99. Epub 2007 Oct 25.</citation>
    <PMID>17996996</PMID>
  </reference>
  <reference>
    <citation>T Nolan et al. A novel Haemophilus influenzae type b - meningococcal serogroups C and Y conjugate (Hib-MenCY-TT) vaccine induces persistent immune responses and immune memory. Abstract presented at Pediatric Academic Societies' (PAS) Annual meeting. San Francisco, California, US, 29 April to 2 May 2006.</citation>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2005</study_first_posted>
  <results_first_submitted>June 15, 2012</results_first_submitted>
  <results_first_submitted_qc>June 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2012</results_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Invasive bacterial disease caused by Hib</keyword>
  <keyword>Neisseria meningitidis serogroups C &amp; Y</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Fondaparinux</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>792014/001</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>792014/001</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>792014/001</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>792014/001</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>792014/001</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 409 subjects enrolled, two subjects were determined to be ineligible for enrolment and were actually never vaccinated. Not all subjects that started the primary vaccination course returned for the polysaccharide challenge dose administration.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenHibrix Formulation 1 Group</title>
          <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="P2">
          <title>MenHibrix Formulation 2 Group</title>
          <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="P3">
          <title>MenHibrix Formulation 3 Group</title>
          <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="P4">
          <title>Menjugate Group</title>
          <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="P5">
          <title>ActHIB Group</title>
          <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Vaccination Course</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Polysaccharide Challenge Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenHibrix Formulation 1 Group</title>
          <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="B2">
          <title>MenHibrix Formulation 2 Group</title>
          <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="B3">
          <title>MenHibrix Formulation 3 Group</title>
          <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Menjugate Group</title>
          <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="B5">
          <title>ActHIB Group</title>
          <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="81"/>
            <count group_id="B5" value="82"/>
            <count group_id="B6" value="407"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="1.39"/>
                    <measurement group_id="B2" value="8.3" spread="1.46"/>
                    <measurement group_id="B3" value="8.2" spread="1.65"/>
                    <measurement group_id="B4" value="8.0" spread="1.65"/>
                    <measurement group_id="B5" value="8.1" spread="1.43"/>
                    <measurement group_id="B6" value="8.1" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 1 Milligram Per Milliliter</title>
        <description>The cut-off concentration assessed was 1 milligram per milliliter (mg/mL).</description>
        <time_frame>One month after primary vaccination (Month 5)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component, for at least one blood sample during the primary vaccination course.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to 1 Milligram Per Milliliter</title>
          <description>The cut-off concentration assessed was 1 milligram per milliliter (mg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component, for at least one blood sample during the primary vaccination course.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup C (MenC) Titers Greater Than or Equal to 1:8</title>
        <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
        <time_frame>One month after primary vaccination (Month 5)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component, for at least one blood sample during the primary vaccination course.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup C (MenC) Titers Greater Than or Equal to 1:8</title>
          <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component, for at least one blood sample during the primary vaccination course.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup Y (MenY) Titers Greater Than or Equal to 1:8</title>
        <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
        <time_frame>One month after primary vaccination (Month 5)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component, for at least one blood sample during the primary vaccination course.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup Y (MenY) Titers Greater Than or Equal to 1:8</title>
          <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity, including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component, for at least one blood sample during the primary vaccination course.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup C (MenC) Titers Greater Than or Equal to 1:8</title>
        <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
        <time_frame>Prior to vaccination (Day 0), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup C (MenC) Titers Greater Than or Equal to 1:8</title>
          <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 68; 66; 63; 66; 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 69; 71; 73; 74; 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="67"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (N= 69; 73; 71; 79; 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup C (MenC) Titers</title>
        <description>Titers were presented as geometric mean titers (GMTs) expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup C (MenC) Titers</title>
          <description>Titers were presented as geometric mean titers (GMTs) expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 68; 66; 63; 66; 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="3.9" upper_limit="4.7"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.1" upper_limit="6.6"/>
                    <measurement group_id="O3" value="4.2" lower_limit="3.9" upper_limit="4.6"/>
                    <measurement group_id="O4" value="4.2" lower_limit="4.0" upper_limit="4.5"/>
                    <measurement group_id="O5" value="4.1" lower_limit="3.9" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 69; 76; 72; 74; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1293.1" lower_limit="1027.7" upper_limit="1627.1"/>
                    <measurement group_id="O2" value="1065.6" lower_limit="858.8" upper_limit="1322.3"/>
                    <measurement group_id="O3" value="968.4" lower_limit="770.8" upper_limit="1216.6"/>
                    <measurement group_id="O4" value="1931.9" lower_limit="1541.2" upper_limit="2421.6"/>
                    <measurement group_id="O5" value="4.2" lower_limit="3.8" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 69; 71; 73; 74; 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.5" lower_limit="190.7" upper_limit="355.8"/>
                    <measurement group_id="O2" value="214.2" lower_limit="163.5" upper_limit="280.7"/>
                    <measurement group_id="O3" value="199.8" lower_limit="143.8" upper_limit="277.6"/>
                    <measurement group_id="O4" value="170.8" lower_limit="113.2" upper_limit="257.7"/>
                    <measurement group_id="O5" value="4.9" lower_limit="4.2" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (N= 69; 73; 71; 79; 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1985.5" lower_limit="1542.6" upper_limit="2555.8"/>
                    <measurement group_id="O2" value="919.5" lower_limit="692.3" upper_limit="1221.2"/>
                    <measurement group_id="O3" value="1530.4" lower_limit="1119.6" upper_limit="2091.8"/>
                    <measurement group_id="O4" value="774.8" lower_limit="536.7" upper_limit="1118.5"/>
                    <measurement group_id="O5" value="9.0" lower_limit="6.4" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With rSBA-MenY Titers Greater Than or Equal to 1:8</title>
        <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
        <time_frame>Prior to vaccination (Day 0), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With rSBA-MenY Titers Greater Than or Equal to 1:8</title>
          <description>The cut-off titer assessed was a dilution of 1:8. Titers were expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 68; 65; 58; 63; 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 69; 69; 70; 71; 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (N= 68; 71; 70; 77; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup Y (MenY) Titers</title>
        <description>Titers were presented as geometric mean titers (GMTs) expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Activity Using Baby Rabbit Complement (rSBA)- Neisseria Meningitidis Serogroup Y (MenY) Titers</title>
          <description>Titers were presented as geometric mean titers (GMTs) expressed as the reciprocal of the dilution resulting in 50 percent inhibition.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 68; 65; 58; 63; 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="4.0" upper_limit="5.4"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.3" upper_limit="7.2"/>
                    <measurement group_id="O3" value="5.1" lower_limit="4.1" upper_limit="6.3"/>
                    <measurement group_id="O4" value="6.3" lower_limit="4.7" upper_limit="8.4"/>
                    <measurement group_id="O5" value="4.9" lower_limit="4.0" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 67; 68; 69; 68; 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="843.5" lower_limit="640.1" upper_limit="1111.7"/>
                    <measurement group_id="O2" value="1020.0" lower_limit="790.0" upper_limit="1316.8"/>
                    <measurement group_id="O3" value="741.8" lower_limit="538.0" upper_limit="1022.9"/>
                    <measurement group_id="O4" value="6.9" lower_limit="5.0" upper_limit="9.5"/>
                    <measurement group_id="O5" value="7.3" lower_limit="5.2" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 69; 69; 70; 71; 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.5" lower_limit="78.6" upper_limit="167.0"/>
                    <measurement group_id="O2" value="139.6" lower_limit="86.8" upper_limit="224.7"/>
                    <measurement group_id="O3" value="129.9" lower_limit="87.1" upper_limit="193.7"/>
                    <measurement group_id="O4" value="10.0" lower_limit="6.7" upper_limit="15.0"/>
                    <measurement group_id="O5" value="13.4" lower_limit="8.6" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (N= 68; 71; 70; 77; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1838.0" lower_limit="1427.9" upper_limit="2366.0"/>
                    <measurement group_id="O2" value="1539.8" lower_limit="1165.4" upper_limit="2034.5"/>
                    <measurement group_id="O3" value="1653.8" lower_limit="1202.5" upper_limit="2274.4"/>
                    <measurement group_id="O4" value="18.8" lower_limit="12.1" upper_limit="29.4"/>
                    <measurement group_id="O5" value="32.0" lower_limit="19.7" upper_limit="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-polysaccharide C (PSC) Antibody Concentration Greater Than or Equal to 30 Micrograms Per Milliliter (µg/mL)</title>
        <description>The cut-off concentration assessed was 30 micrograms per milliliter (µg/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-polysaccharide C (PSC) Antibody Concentration Greater Than or Equal to 30 Micrograms Per Milliliter (µg/mL)</title>
          <description>The cut-off concentration assessed was 30 micrograms per milliliter (µg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 54; 54; 49; 56; 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 63; 65; 61; 62; 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 63; 68; 61; 74; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (N= 71; 70; 71; 76; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-polysaccharide C (PSC) Antibody Concentration</title>
        <description>Titers are presented as Geometric Mean Titers (GMTs) expressed as micrograms per milliliter (µg/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-polysaccharide C (PSC) Antibody Concentration</title>
          <description>Titers are presented as Geometric Mean Titers (GMTs) expressed as micrograms per milliliter (µg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>microgram per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 54; 54; 49; 56; 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.15" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.15" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.15" upper_limit="0.19"/>
                    <measurement group_id="O4" value="0.17" lower_limit="0.15" upper_limit="0.20"/>
                    <measurement group_id="O5" value="0.17" lower_limit="0.15" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 63; 65; 61; 62; 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.02" lower_limit="9.90" upper_limit="14.59"/>
                    <measurement group_id="O2" value="12.09" lower_limit="10.59" upper_limit="13.81"/>
                    <measurement group_id="O3" value="9.95" lower_limit="8.34" upper_limit="11.87"/>
                    <measurement group_id="O4" value="15.36" lower_limit="12.67" upper_limit="18.62"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 63; 68; 61; 74; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" lower_limit="2.52" upper_limit="3.85"/>
                    <measurement group_id="O2" value="3.10" lower_limit="2.64" upper_limit="3.64"/>
                    <measurement group_id="O3" value="2.74" lower_limit="2.29" upper_limit="3.27"/>
                    <measurement group_id="O4" value="2.87" lower_limit="2.23" upper_limit="3.71"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (N= 71; 70; 71; 76; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.47" lower_limit="9.25" upper_limit="14.22"/>
                    <measurement group_id="O2" value="7.94" lower_limit="6.42" upper_limit="9.81"/>
                    <measurement group_id="O3" value="10.96" lower_limit="8.63" upper_limit="13.91"/>
                    <measurement group_id="O4" value="7.56" lower_limit="6.17" upper_limit="9.26"/>
                    <measurement group_id="O5" value="1.49" lower_limit="1.23" upper_limit="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-polysaccharide Y (PSY) Antibody Concentration Greater Than or Equal to 30 Micrograms Per Milliliter (µg/mL)</title>
        <description>The cut-off concentration assessed was 30 micrograms per milliliter (µg/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-polysaccharide Y (PSY) Antibody Concentration Greater Than or Equal to 30 Micrograms Per Milliliter (µg/mL)</title>
          <description>The cut-off concentration assessed was 30 micrograms per milliliter (µg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 51; 51; 47; 56; 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 67; 70; 72; 66; 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 70; 69; 71; 76; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (N= 69; 71; 71; 77; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-polysaccharide Y (PSY) Antibody Concentration</title>
        <description>Titers are presented as Geometric Mean Titers (GMTs) expressed as micrograms per milliliter (µg/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-polysaccharide Y (PSY) Antibody Concentration</title>
          <description>Titers are presented as Geometric Mean Titers (GMTs) expressed as micrograms per milliliter (µg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>Microgram per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 51; 51; 47; 56; 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.15" upper_limit="0.19"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.15" upper_limit="0.23"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.15" upper_limit="0.19"/>
                    <measurement group_id="O4" value="0.20" lower_limit="0.16" upper_limit="0.26"/>
                    <measurement group_id="O5" value="0.19" lower_limit="0.16" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 67; 70; 72; 66; 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.22" lower_limit="15.42" upper_limit="23.95"/>
                    <measurement group_id="O2" value="19.09" lower_limit="15.44" upper_limit="23.59"/>
                    <measurement group_id="O3" value="15.83" lower_limit="12.64" upper_limit="19.82"/>
                    <measurement group_id="O4" value="0.16" lower_limit="0.15" upper_limit="0.17"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 70; 69; 71; 76; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" lower_limit="4.20" upper_limit="6.60"/>
                    <measurement group_id="O2" value="5.20" lower_limit="4.17" upper_limit="6.49"/>
                    <measurement group_id="O3" value="4.10" lower_limit="3.22" upper_limit="5.23"/>
                    <measurement group_id="O4" value="0.15" lower_limit="0.15" upper_limit="0.15"/>
                    <measurement group_id="O5" value="0.15" lower_limit="0.15" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (N= 69; 71; 71; 77; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.95" lower_limit="39.80" upper_limit="57.77"/>
                    <measurement group_id="O2" value="37.15" lower_limit="29.16" upper_limit="47.32"/>
                    <measurement group_id="O3" value="51.12" lower_limit="38.71" upper_limit="67.52"/>
                    <measurement group_id="O4" value="1.37" lower_limit="1.05" upper_limit="1.79"/>
                    <measurement group_id="O5" value="1.33" lower_limit="1.02" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-PRP Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</title>
        <description>The cut-off concentrations assessed were 0.15 micrograms per milliliter (µg/mL) and 1 µg/mL.</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-PRP Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values</title>
          <description>The cut-off concentrations assessed were 0.15 micrograms per milliliter (µg/mL) and 1 µg/mL.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 ≥ 0.15 µg/mL (N= 68; 70; 67; 67; 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 ≥ 0.15 µg/mL (N= 74; 76; 70; 74; 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="73"/>
                    <measurement group_id="O5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 ≥ 0.15 µg/mL (N= 70; 72; 73; 76; 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 ≥ 0.15 µg/mL (N= 68; 73; 71; 79; 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 ≥ 1 µg/mL (N= 68; 70; 67; 67; 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 ≥ 1 µg/mL (N= 74; 76; 70; 74; 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 ≥ 1 µg/mL (N= 70; 72; 73; 76; 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 ≥ 1 µg/mL (N= 68; 73; 71; 79; 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="57"/>
                    <measurement group_id="O5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PRP Antibody Concentration</title>
        <description>Concentrations are presented as GMCs and expressed as µg/mL.</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5), before administration of the polysaccharide challenge dose (Month 10) and one month after administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PRP Antibody Concentration</title>
          <description>Concentrations are presented as GMCs and expressed as µg/mL.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10/Month 11 data.</population>
          <units>Microgram per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 68; 70; 67; 67; 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.152" lower_limit="0.120" upper_limit="0.194"/>
                    <measurement group_id="O2" value="0.224" lower_limit="0.164" upper_limit="0.305"/>
                    <measurement group_id="O3" value="0.214" lower_limit="0.166" upper_limit="0.276"/>
                    <measurement group_id="O4" value="0.172" lower_limit="0.132" upper_limit="0.223"/>
                    <measurement group_id="O5" value="0.201" lower_limit="0.153" upper_limit="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 70; 74; 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.441" lower_limit="5.315" upper_limit="7.805"/>
                    <measurement group_id="O2" value="7.324" lower_limit="5.877" upper_limit="9.127"/>
                    <measurement group_id="O3" value="5.577" lower_limit="4.375" upper_limit="7.110"/>
                    <measurement group_id="O4" value="4.465" lower_limit="3.399" upper_limit="5.865"/>
                    <measurement group_id="O5" value="5.714" lower_limit="4.538" upper_limit="7.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 70; 72; 73; 76; 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.386" lower_limit="1.134" upper_limit="1.693"/>
                    <measurement group_id="O2" value="1.383" lower_limit="1.092" upper_limit="1.751"/>
                    <measurement group_id="O3" value="1.148" lower_limit="0.914" upper_limit="1.441"/>
                    <measurement group_id="O4" value="0.949" lower_limit="0.728" upper_limit="1.238"/>
                    <measurement group_id="O5" value="1.141" lower_limit="0.868" upper_limit="1.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 11 (N= 68; 73; 71; 79; 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.653" lower_limit="6.701" upper_limit="11.173"/>
                    <measurement group_id="O2" value="6.750" lower_limit="5.002" upper_limit="9.107"/>
                    <measurement group_id="O3" value="5.112" lower_limit="3.878" upper_limit="6.739"/>
                    <measurement group_id="O4" value="2.512" lower_limit="1.837" upper_limit="3.435"/>
                    <measurement group_id="O5" value="3.283" lower_limit="2.380" upper_limit="4.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for Anti-diphtheria Antibodies</title>
        <description>Seroprotection is defined as anti-diphtheria toxoid antibody concentration greater than or equal to 0.1 International Units per Milliliter (IU/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for Anti-diphtheria Antibodies</title>
          <description>Seroprotection is defined as anti-diphtheria toxoid antibody concentration greater than or equal to 0.1 International Units per Milliliter (IU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 68; 70; 65; 69; 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 78; 78; 75; 80; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="74"/>
                    <measurement group_id="O5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-diphtheria Antibody Concentrations</title>
        <description>Concentrations are presented as GMCs and expressed as International Units per Milliliter (IU/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-diphtheria Antibody Concentrations</title>
          <description>Concentrations are presented as GMCs and expressed as International Units per Milliliter (IU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>International Units per Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 68; 70; 65; 69; 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.090" lower_limit="0.074" upper_limit="0.110"/>
                    <measurement group_id="O2" value="0.098" lower_limit="0.077" upper_limit="0.123"/>
                    <measurement group_id="O3" value="0.101" lower_limit="0.080" upper_limit="0.127"/>
                    <measurement group_id="O4" value="0.090" lower_limit="0.074" upper_limit="0.110"/>
                    <measurement group_id="O5" value="0.093" lower_limit="0.074" upper_limit="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.721" lower_limit="1.480" upper_limit="2.003"/>
                    <measurement group_id="O2" value="1.797" lower_limit="1.508" upper_limit="2.141"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.706" upper_limit="2.346"/>
                    <measurement group_id="O4" value="1.845" lower_limit="1.598" upper_limit="2.130"/>
                    <measurement group_id="O5" value="1.970" lower_limit="1.760" upper_limit="2.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 78; 78; 75; 80; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.513" lower_limit="0.423" upper_limit="0.622"/>
                    <measurement group_id="O2" value="0.505" lower_limit="0.410" upper_limit="0.621"/>
                    <measurement group_id="O3" value="0.519" lower_limit="0.423" upper_limit="0.638"/>
                    <measurement group_id="O4" value="0.405" lower_limit="0.330" upper_limit="0.497"/>
                    <measurement group_id="O5" value="0.543" lower_limit="0.467" upper_limit="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for Anti-tetanus Antibodies</title>
        <description>Seroprotection is defined as anti-tetanus toxoid antibody concentration greater than or equal to 0.1 International Units per Milliliter (IU/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for Anti-tetanus Antibodies</title>
          <description>Seroprotection is defined as anti-tetanus toxoid antibody concentration greater than or equal to 0.1 International Units per Milliliter (IU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 62; 64; 60; 60; 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="57"/>
                    <measurement group_id="O5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 78; 78; 75; 80; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-tetanus Antibody Concentrations</title>
        <description>Concentrations are presented as GMCs and expressed as International Units per Milliliter (IU/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-tetanus Antibody Concentrations</title>
          <description>Concentrations are presented as GMCs and expressed as International Units per Milliliter (IU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>International Units per Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 62; 64; 60; 60; 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.460" lower_limit="0.343" upper_limit="0.617"/>
                    <measurement group_id="O2" value="0.470" lower_limit="0.364" upper_limit="0.608"/>
                    <measurement group_id="O3" value="0.501" lower_limit="0.386" upper_limit="0.651"/>
                    <measurement group_id="O4" value="0.562" lower_limit="0.435" upper_limit="0.727"/>
                    <measurement group_id="O5" value="0.533" lower_limit="0.403" upper_limit="0.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.301" lower_limit="2.909" upper_limit="3.747"/>
                    <measurement group_id="O2" value="3.816" lower_limit="3.340" upper_limit="4.360"/>
                    <measurement group_id="O3" value="3.366" lower_limit="2.974" upper_limit="3.810"/>
                    <measurement group_id="O4" value="1.877" lower_limit="1.603" upper_limit="2.197"/>
                    <measurement group_id="O5" value="2.033" lower_limit="1.773" upper_limit="2.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 78; 78; 75; 80; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.114" lower_limit="0.967" upper_limit="1.283"/>
                    <measurement group_id="O2" value="1.307" lower_limit="1.119" upper_limit="1.528"/>
                    <measurement group_id="O3" value="1.062" lower_limit="0.905" upper_limit="1.246"/>
                    <measurement group_id="O4" value="0.603" lower_limit="0.500" upper_limit="0.728"/>
                    <measurement group_id="O5" value="0.756" lower_limit="0.633" upper_limit="0.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroseropositive for Anti-filamentus Haemagglutinin (FHA) Antibodies</title>
        <description>Seropositivity is defined as anti-FHA antibody concentration greater than or equal to 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroseropositive for Anti-filamentus Haemagglutinin (FHA) Antibodies</title>
          <description>Seropositivity is defined as anti-FHA antibody concentration greater than or equal to 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 64; 69; 65; 67; 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 78; 78; 75; 79; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti- FHA Antibody Concentrations</title>
        <description>Concentrations are presented as GMCs and expressed as Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti- FHA Antibody Concentrations</title>
          <description>Concentrations are presented as GMCs and expressed as Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
          <units>ELISA Units per Milliliter (EL.U/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 64; 69; 65; 67; 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="4.2" upper_limit="6.2"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.7" upper_limit="5.7"/>
                    <measurement group_id="O3" value="5.8" lower_limit="4.8" upper_limit="7.1"/>
                    <measurement group_id="O4" value="7.4" lower_limit="5.8" upper_limit="9.5"/>
                    <measurement group_id="O5" value="4.8" lower_limit="3.9" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.2" lower_limit="116.4" upper_limit="161.7"/>
                    <measurement group_id="O2" value="141.5" lower_limit="122.1" upper_limit="163.9"/>
                    <measurement group_id="O3" value="136.2" lower_limit="118.0" upper_limit="157.2"/>
                    <measurement group_id="O4" value="132.1" lower_limit="114.1" upper_limit="153.0"/>
                    <measurement group_id="O5" value="146.7" lower_limit="124.8" upper_limit="172.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 78; 78; 75; 79; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" lower_limit="40.6" upper_limit="60.0"/>
                    <measurement group_id="O2" value="50.9" lower_limit="41.4" upper_limit="62.6"/>
                    <measurement group_id="O3" value="44.3" lower_limit="35.7" upper_limit="55.0"/>
                    <measurement group_id="O4" value="39.9" lower_limit="33.9" upper_limit="47.0"/>
                    <measurement group_id="O5" value="50.2" lower_limit="41.6" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroseropositive for Anti-pertactin (PRN) Antibodies</title>
        <description>Seropositivity is defined as anti-PRN antibody concentration greater than or equal to 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroseropositive for Anti-pertactin (PRN) Antibodies</title>
          <description>Seropositivity is defined as anti-PRN antibody concentration greater than or equal to 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 67; 63; 67; 68; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 78; 78; 75; 80; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="73"/>
                    <measurement group_id="O5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-PRN Antibody Concentrations</title>
        <description>Concentrations are presented as GMCs and expressed as Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-PRN Antibody Concentrations</title>
          <description>Concentrations are presented as GMCs and expressed as Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
          <units>ELISA Units per Milliliter (EL.U/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 67; 63; 67; 68; 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="3.2" upper_limit="4.7"/>
                    <measurement group_id="O2" value="4.7" lower_limit="3.7" upper_limit="5.8"/>
                    <measurement group_id="O3" value="4.6" lower_limit="3.7" upper_limit="5.7"/>
                    <measurement group_id="O4" value="5.3" lower_limit="4.1" upper_limit="6.8"/>
                    <measurement group_id="O5" value="4.4" lower_limit="3.6" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.3" lower_limit="107.4" upper_limit="153.1"/>
                    <measurement group_id="O2" value="120.7" lower_limit="98.6" upper_limit="147.7"/>
                    <measurement group_id="O3" value="106.2" lower_limit="89.3" upper_limit="126.3"/>
                    <measurement group_id="O4" value="112.9" lower_limit="91.6" upper_limit="139.1"/>
                    <measurement group_id="O5" value="137.8" lower_limit="118.2" upper_limit="160.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 78; 78; 75; 80; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" lower_limit="29.5" upper_limit="44.3"/>
                    <measurement group_id="O2" value="31.8" lower_limit="25.2" upper_limit="40.0"/>
                    <measurement group_id="O3" value="27.3" lower_limit="22.1" upper_limit="33.8"/>
                    <measurement group_id="O4" value="27.2" lower_limit="21.5" upper_limit="34.4"/>
                    <measurement group_id="O5" value="35.8" lower_limit="29.7" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroseropositive for Anti-pertussis Toxoid (PT) Antibodies</title>
        <description>Seropositivity is defined as anti-PT antibody concentration greater than or equal to 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroseropositive for Anti-pertussis Toxoid (PT) Antibodies</title>
          <description>Seropositivity is defined as anti-PT antibody concentration greater than or equal to 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 65; 66; 65; 63; 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="77"/>
                    <measurement group_id="O5" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 77; 76; 73; 78; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti- PT Antibody Concentrations</title>
        <description>Concentrations are presented as GMCs and expressed as Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti- PT Antibody Concentrations</title>
          <description>Concentrations are presented as GMCs and expressed as Enzyme-Linked Immunosorbent Assay (ELISA) Units per Milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
          <units>ELISA Units per Milliliter (EL.U/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 65; 66; 65; 63; 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="2.5" upper_limit="2.9"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2.5" upper_limit="2.9"/>
                    <measurement group_id="O3" value="2.8" lower_limit="2.5" upper_limit="3.1"/>
                    <measurement group_id="O4" value="3.1" lower_limit="2.7" upper_limit="3.5"/>
                    <measurement group_id="O5" value="2.7" lower_limit="2.4" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 74; 76; 74; 77; 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1" lower_limit="48.4" upper_limit="62.8"/>
                    <measurement group_id="O2" value="55.2" lower_limit="47.9" upper_limit="63.6"/>
                    <measurement group_id="O3" value="53.7" lower_limit="46.1" upper_limit="62.5"/>
                    <measurement group_id="O4" value="49.7" lower_limit="43.2" upper_limit="57.2"/>
                    <measurement group_id="O5" value="54.8" lower_limit="47.3" upper_limit="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 77; 76; 73; 78; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="10.0" upper_limit="13.6"/>
                    <measurement group_id="O2" value="11.6" lower_limit="9.6" upper_limit="14.0"/>
                    <measurement group_id="O3" value="9.9" lower_limit="8.2" upper_limit="12.1"/>
                    <measurement group_id="O4" value="8.2" lower_limit="6.8" upper_limit="9.8"/>
                    <measurement group_id="O5" value="9.8" lower_limit="8.1" upper_limit="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for Anti-hepatitis B (HBs) Antibodies</title>
        <description>Seroprotection is defined as anti-HBs antibody concentration greater than or equal to 10 Milli-International Units per Milliliter (mIU/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for Anti-hepatitis B (HBs) Antibodies</title>
          <description>Seroprotection is defined as anti-HBs antibody concentration greater than or equal to 10 Milli-International Units per Milliliter (mIU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 57; 55; 56; 52; 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 72; 74; 74; 76; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 74; 70; 70; 75; 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="72"/>
                    <measurement group_id="O5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti- HBs Antibody Concentrations</title>
        <description>Concentrations are presented as GMCs and expressed as Milli-International Units per Milliliter (mIU/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti- HBs Antibody Concentrations</title>
          <description>Concentrations are presented as GMCs and expressed as Milli-International Units per Milliliter (mIU/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
          <units>Milli-International Units per Milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (N= 57; 55; 56; 52; 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="8.1" upper_limit="23.1"/>
                    <measurement group_id="O2" value="12.2" lower_limit="7.8" upper_limit="19.2"/>
                    <measurement group_id="O3" value="10.0" lower_limit="6.9" upper_limit="14.5"/>
                    <measurement group_id="O4" value="10.1" lower_limit="7.1" upper_limit="14.4"/>
                    <measurement group_id="O5" value="18.8" lower_limit="11.1" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5 (N= 72; 74; 74; 76; 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1769.2" lower_limit="1276.4" upper_limit="2452.2"/>
                    <measurement group_id="O2" value="1840.7" lower_limit="1467.3" upper_limit="2309.0"/>
                    <measurement group_id="O3" value="1652.6" lower_limit="1301.2" upper_limit="2098.8"/>
                    <measurement group_id="O4" value="1752.2" lower_limit="1373.3" upper_limit="2235.6"/>
                    <measurement group_id="O5" value="1609.7" lower_limit="1191.1" upper_limit="2175.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 10 (N= 74; 70; 70; 75; 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452.3" lower_limit="311.6" upper_limit="656.6"/>
                    <measurement group_id="O2" value="490.5" lower_limit="346.6" upper_limit="694.1"/>
                    <measurement group_id="O3" value="452.9" lower_limit="329.7" upper_limit="622.3"/>
                    <measurement group_id="O4" value="390.5" lower_limit="278.4" upper_limit="547.8"/>
                    <measurement group_id="O5" value="534.9" lower_limit="378.7" upper_limit="755.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for Anti-poliovirus Types 1, 2 and 3 Antibodies</title>
        <description>Seroprotection is defined as anti-polio antibody titer greater than or equal to 1:8 dilution.</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for Anti-poliovirus Types 1, 2 and 3 Antibodies</title>
          <description>Seroprotection is defined as anti-polio antibody titer greater than or equal to 1:8 dilution.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Polio-1 Day 0 (N= 56; 58; 50; 56; 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-1 Month 5 (N= 62; 68; 66; 66; 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-1 Month 10 (N= 71; 69; 70; 76; 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-2 Day 0 (N= 56; 59; 50; 55; 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-2 Month 5 (N= 59; 66; 64; 66; 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-2 Month 10 (N= 71; 70; 69; 75; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="71"/>
                    <measurement group_id="O5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-3 Day 0 (N= 56; 59; 50; 56; 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-3 Month 5 (N= 62; 68; 66; 66; 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="65"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-3 Month 10 (N= 71; 70; 69; 76; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-poliovirus Types 1, 2 and 3 Antibody Titers</title>
        <description>Titers are presented as GMTs and expressed in terms of the 50 % inhibitory dilution.</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-poliovirus Types 1, 2 and 3 Antibody Titers</title>
          <description>Titers are presented as GMTs and expressed in terms of the 50 % inhibitory dilution.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="76"/>
                <count group_id="O5" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Polio-1 Day 0 (N= 56; 58; 50; 56; 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" lower_limit="24.6" upper_limit="54.8"/>
                    <measurement group_id="O2" value="33.3" lower_limit="23.2" upper_limit="47.6"/>
                    <measurement group_id="O3" value="32.9" lower_limit="21.7" upper_limit="49.7"/>
                    <measurement group_id="O4" value="52.3" lower_limit="34.9" upper_limit="78.2"/>
                    <measurement group_id="O5" value="36.6" lower_limit="24.6" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-1 Month 5 (N= 62; 68; 66; 66; 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="669.6" lower_limit="507.5" upper_limit="883.4"/>
                    <measurement group_id="O2" value="476.8" lower_limit="364.0" upper_limit="624.4"/>
                    <measurement group_id="O3" value="574.7" lower_limit="436.2" upper_limit="757.1"/>
                    <measurement group_id="O4" value="454.0" lower_limit="337.5" upper_limit="610.7"/>
                    <measurement group_id="O5" value="517.6" lower_limit="396.9" upper_limit="674.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-1 Month 10 (N= 71; 69; 70; 76; 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.8" lower_limit="129.3" upper_limit="239.1"/>
                    <measurement group_id="O2" value="120.6" lower_limit="83.8" upper_limit="173.7"/>
                    <measurement group_id="O3" value="162.4" lower_limit="120.2" upper_limit="219.4"/>
                    <measurement group_id="O4" value="116.4" lower_limit="86.6" upper_limit="156.5"/>
                    <measurement group_id="O5" value="166.4" lower_limit="124.7" upper_limit="222.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-2 Day 0 (N= 56; 59; 50; 55; 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="11.2" upper_limit="19.9"/>
                    <measurement group_id="O2" value="13.8" lower_limit="10.3" upper_limit="18.3"/>
                    <measurement group_id="O3" value="15.9" lower_limit="11.4" upper_limit="22.1"/>
                    <measurement group_id="O4" value="17.2" lower_limit="12.8" upper_limit="23.3"/>
                    <measurement group_id="O5" value="17.1" lower_limit="12.7" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-2 Month 5 (N= 59; 66; 64; 66; 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533.8" lower_limit="393.3" upper_limit="724.4"/>
                    <measurement group_id="O2" value="369.8" lower_limit="273.4" upper_limit="500.0"/>
                    <measurement group_id="O3" value="408.0" lower_limit="297.6" upper_limit="559.4"/>
                    <measurement group_id="O4" value="348.9" lower_limit="265.3" upper_limit="458.8"/>
                    <measurement group_id="O5" value="368.0" lower_limit="264.0" upper_limit="512.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-2 Month 10 (N= 71; 70; 69; 75; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.8" lower_limit="104.1" upper_limit="187.8"/>
                    <measurement group_id="O2" value="94.1" lower_limit="67.5" upper_limit="131.3"/>
                    <measurement group_id="O3" value="110.1" lower_limit="77.0" upper_limit="157.4"/>
                    <measurement group_id="O4" value="89.6" lower_limit="63.4" upper_limit="126.7"/>
                    <measurement group_id="O5" value="88.3" lower_limit="61.6" upper_limit="126.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-3 Day 0 (N= 56; 59; 50; 56; 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="5.3" upper_limit="7.8"/>
                    <measurement group_id="O2" value="6.6" lower_limit="5.2" upper_limit="8.3"/>
                    <measurement group_id="O3" value="7.9" lower_limit="6.2" upper_limit="10.1"/>
                    <measurement group_id="O4" value="7.7" lower_limit="5.8" upper_limit="10.1"/>
                    <measurement group_id="O5" value="8.0" lower_limit="6.1" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-3 Month 5 (N= 62; 68; 66; 66; 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1266.3" lower_limit="992.1" upper_limit="1616.2"/>
                    <measurement group_id="O2" value="1034.8" lower_limit="778.8" upper_limit="1374.8"/>
                    <measurement group_id="O3" value="1062.2" lower_limit="809.2" upper_limit="1394.2"/>
                    <measurement group_id="O4" value="1084.9" lower_limit="804.2" upper_limit="1463.7"/>
                    <measurement group_id="O5" value="945.5" lower_limit="695.9" upper_limit="1284.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polio-3 Month 10 (N= 71; 70; 69; 76; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348.4" lower_limit="260.0" upper_limit="466.9"/>
                    <measurement group_id="O2" value="263.8" lower_limit="194.2" upper_limit="358.3"/>
                    <measurement group_id="O3" value="250.9" lower_limit="184.1" upper_limit="342.1"/>
                    <measurement group_id="O4" value="264.0" lower_limit="192.1" upper_limit="362.9"/>
                    <measurement group_id="O5" value="203.9" lower_limit="139.6" upper_limit="297.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-pneumococcal Antibody Concentrations Greater Than or Equal to Pre-defined Cut-off Values</title>
        <description>Pneumococcal antibodies assessed included anti-4, anti-6B, anti-9V, anti-14, anti-18C, anti-19F and anti-23F antibodies. The cut-off values assessed were 0.05 and 0.2 micrograms per milliliter (µg/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-pneumococcal Antibody Concentrations Greater Than or Equal to Pre-defined Cut-off Values</title>
          <description>Pneumococcal antibodies assessed included anti-4, anti-6B, anti-9V, anti-14, anti-18C, anti-19F and anti-23F antibodies. The cut-off values assessed were 0.05 and 0.2 micrograms per milliliter (µg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for safety, including all vaccinated subjects who had not received a vaccine not specified or forbidden in the protocol, for the Month 10 data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-4 ≥ 0.05 µg/mL Day 0 (N=44;43;39;51;46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 ≥ 0.05 µg/mL Month 5 (N=69;70;69;58;66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 ≥ 0.05 µg/mL Month 10 (N=70;68;66;69;64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B ≥ 0.05 µg/mL Day 0 (N=44;41;39;49;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B ≥ 0.05 µg/mL Month 5 (N=68;70;69;63;65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B ≥ 0.05 µg/mL Month 10 (N=69;63;62;71;62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V ≥ 0.05 µg/mL Day 0 (N=46;42;40;52;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V ≥ 0.05 µg/mL Month 5 (N=68;71;71;62;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V ≥ 0.05 µg/mL Month 10 (N=60;60;56;63;56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 ≥ 0.05 µg/mL Day 0 (N=31;33;31;41;43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 ≥ 0.05 µg/mL Month 5 (N=65;65;68;49;65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 ≥ 0.05 µg/mL Month 10 (N=68;67;64;69;61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C ≥ 0.05 µg/mL Day 0 (N=40;40;37;47;47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C ≥ 0.05 µg/mL Month 5 (N=67;71;72;65;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C ≥ 0.05 µg/mL Month 10 (N=48;52;51;53;46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F ≥ 0.05 µg/mL Day 0 (N=42;42;36;50;45))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F ≥ 0.05 µg/mL Month 5 (N=65;67;66;56;65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F ≥ 0.05 µg/mL Month 10 (N=73;71;65;77;63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F ≥ 0.05 µg/mL Day 0 (N=41;43;38;48;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F ≥ 0.05 µg/mL Month 5 (N=66;68;70;59;66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F ≥ 0.05 µg/mL Month 10 (N=73;69;63;75;65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 ≥ 0.2 µg/mL Day 0 (N=44;43;39;51;46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 ≥ 0.2 µg/mL Month 5 (N=69;70;69;58;66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 ≥ 0.2 µg/mL Month 10 (N=70;68;66;69;64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B ≥ 0.2 µg/mL Day 0 (N=44;41;39;49;49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B ≥ 0.2 µg/mL Month 5 (N=68;70;69;63;65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B ≥ 0.2 µg/mL Month 10 (N=69;63;62;71;62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V ≥ 0.2 µg/mL Day 0 (N=46;42;40;52;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V ≥ 0.2 µg/mL Month 5 (N=68;71;71;62;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V ≥ 0.2 µg/mL Month 10 (N=60;60;56;63;56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 ≥ 0.2 µg/mL Day 0 (N=31;33;31;41;43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 ≥ 0.2 µg/mL Month 5 (N=65;65;68;49;65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 ≥ 0.2 µg/mL Month 10 (N=68;67;64;69;61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C ≥ 0.2 µg/mL Day 0 (N=40;40;37;47;47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C ≥ 0.2 µg/mL Month 5 (N=67;71;72;65;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C ≥ 0.2 µg/mL Month 10 (N=48;52;51;53;46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F ≥ 0.2 µg/mL Day 0 (N=42;42;36;50;45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F ≥ 0.2 µg/mL Month 5 (N=65;67;66;56;65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F ≥ 0.2 µg/mL Month 10 (N=73;71;65;77;63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F ≥ 0.2 µg/mL Day 0 (N=41;43;38;48;48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F ≥ 0.2 µg/mL Month 5 (N=66;68;70;59;66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F ≥ 0.2 µg/mL Month 10 (N=73;69;63;75;65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-pneumococcal Antibody Concentrations</title>
        <description>Pneumococcal antibodies assessed included anti-4, anti-6B, anti-9V, anti-14, anti-18C, anti-19F and anti-23F antibodies. Concentrations are presented as GMCs and expressed as micrograms per milliliter (µg/mL).</description>
        <time_frame>Prior to vaccination (Day 0), one month after the 3-dose primary vaccination course (Month 5) and before administration of the polysaccharide challenge dose (Month 10)</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pneumococcal Antibody Concentrations</title>
          <description>Pneumococcal antibodies assessed included anti-4, anti-6B, anti-9V, anti-14, anti-18C, anti-19F and anti-23F antibodies. Concentrations are presented as GMCs and expressed as micrograms per milliliter (µg/mL).</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity for Day 0/Month5 data and on the Booster ATP cohort for immunogenicity for the Month 10 data.</population>
          <units>Micrograms per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-4 Day 0 (N= 44; 43; 39; 51; 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" lower_limit="0.029" upper_limit="0.046"/>
                    <measurement group_id="O2" value="0.035" lower_limit="0.028" upper_limit="0.043"/>
                    <measurement group_id="O3" value="0.040" lower_limit="0.030" upper_limit="0.053"/>
                    <measurement group_id="O4" value="0.034" lower_limit="0.028" upper_limit="0.040"/>
                    <measurement group_id="O5" value="0.036" lower_limit="0.029" upper_limit="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 Month 5 (N= 69; 70; 69; 58; 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.101" lower_limit="1.780" upper_limit="2.480"/>
                    <measurement group_id="O2" value="2.049" lower_limit="1.718" upper_limit="2.442"/>
                    <measurement group_id="O3" value="2.023" lower_limit="1.729" upper_limit="2.366"/>
                    <measurement group_id="O4" value="0.027" lower_limit="0.024" upper_limit="0.030"/>
                    <measurement group_id="O5" value="2.062" lower_limit="1.787" upper_limit="2.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4 Month 10 (N= 70; 68; 66; 69; 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.495" lower_limit="0.407" upper_limit="0.603"/>
                    <measurement group_id="O2" value="0.528" lower_limit="0.431" upper_limit="0.646"/>
                    <measurement group_id="O3" value="0.508" lower_limit="0.414" upper_limit="0.623"/>
                    <measurement group_id="O4" value="0.026" lower_limit="0.024" upper_limit="0.027"/>
                    <measurement group_id="O5" value="0.450" lower_limit="0.372" upper_limit="0.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B Day 0 (N= 44; 41; 39; 49; 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" lower_limit="0.039" upper_limit="0.078"/>
                    <measurement group_id="O2" value="0.080" lower_limit="0.052" upper_limit="0.123"/>
                    <measurement group_id="O3" value="0.067" lower_limit="0.046" upper_limit="0.099"/>
                    <measurement group_id="O4" value="0.070" lower_limit="0.049" upper_limit="0.101"/>
                    <measurement group_id="O5" value="0.067" lower_limit="0.045" upper_limit="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B Month 5 (N= 68; 70; 69; 63; 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.060" lower_limit="0.744" upper_limit="1.511"/>
                    <measurement group_id="O2" value="1.079" lower_limit="0.808" upper_limit="1.442"/>
                    <measurement group_id="O3" value="0.834" lower_limit="0.567" upper_limit="1.225"/>
                    <measurement group_id="O4" value="0.027" lower_limit="0.025" upper_limit="0.030"/>
                    <measurement group_id="O5" value="0.879" lower_limit="0.604" upper_limit="1.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B Month 10 (N= 69; 63; 62; 71; 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.307" lower_limit="0.223" upper_limit="0.424"/>
                    <measurement group_id="O2" value="0.307" lower_limit="0.223" upper_limit="0.423"/>
                    <measurement group_id="O3" value="0.292" lower_limit="0.215" upper_limit="0.398"/>
                    <measurement group_id="O4" value="0.026" lower_limit="0.025" upper_limit="0.027"/>
                    <measurement group_id="O5" value="0.308" lower_limit="0.220" upper_limit="0.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V Day 0 (N= 46; 42; 40; 52; 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.058" lower_limit="0.040" upper_limit="0.085"/>
                    <measurement group_id="O2" value="0.065" lower_limit="0.044" upper_limit="0.096"/>
                    <measurement group_id="O3" value="0.079" lower_limit="0.051" upper_limit="0.121"/>
                    <measurement group_id="O4" value="0.059" lower_limit="0.043" upper_limit="0.080"/>
                    <measurement group_id="O5" value="0.055" lower_limit="0.039" upper_limit="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V Month 5 (N= 68; 71; 71; 62; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.102" lower_limit="2.563" upper_limit="3.754"/>
                    <measurement group_id="O2" value="2.363" lower_limit="1.822" upper_limit="3.066"/>
                    <measurement group_id="O3" value="2.823" lower_limit="2.376" upper_limit="3.354"/>
                    <measurement group_id="O4" value="0.028" lower_limit="0.024" upper_limit="0.033"/>
                    <measurement group_id="O5" value="2.651" lower_limit="2.079" upper_limit="3.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V Month 10 (N= 60; 60; 56; 63; 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.818" lower_limit="0.656" upper_limit="1.020"/>
                    <measurement group_id="O2" value="0.721" lower_limit="0.555" upper_limit="0.937"/>
                    <measurement group_id="O3" value="0.933" lower_limit="0.758" upper_limit="1.147"/>
                    <measurement group_id="O4" value="0.030" lower_limit="0.025" upper_limit="0.035"/>
                    <measurement group_id="O5" value="0.881" lower_limit="0.742" upper_limit="1.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 Day 0 (N= 31; 33; 31; 41; 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.367" lower_limit="0.203" upper_limit="0.664"/>
                    <measurement group_id="O2" value="0.227" lower_limit="0.121" upper_limit="0.427"/>
                    <measurement group_id="O3" value="0.258" lower_limit="0.143" upper_limit="0.467"/>
                    <measurement group_id="O4" value="0.394" lower_limit="0.253" upper_limit="0.612"/>
                    <measurement group_id="O5" value="0.388" lower_limit="0.247" upper_limit="0.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 Month 5 (N= 65; 65; 68; 49; 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.095" lower_limit="3.037" upper_limit="5.520"/>
                    <measurement group_id="O2" value="5.592" lower_limit="4.238" upper_limit="7.378"/>
                    <measurement group_id="O3" value="4.309" lower_limit="3.306" upper_limit="5.616"/>
                    <measurement group_id="O4" value="0.062" lower_limit="0.043" upper_limit="0.090"/>
                    <measurement group_id="O5" value="4.372" lower_limit="3.211" upper_limit="5.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14 Month 10 (N= 68; 67; 64; 69; 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.362" lower_limit="1.786" upper_limit="3.124"/>
                    <measurement group_id="O2" value="2.767" lower_limit="2.149" upper_limit="3.563"/>
                    <measurement group_id="O3" value="2.549" lower_limit="1.968" upper_limit="3.304"/>
                    <measurement group_id="O4" value="0.039" lower_limit="0.030" upper_limit="0.051"/>
                    <measurement group_id="O5" value="2.379" lower_limit="1.807" upper_limit="3.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C Day 0 (N= 40; 40; 37; 47; 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073" lower_limit="0.049" upper_limit="0.109"/>
                    <measurement group_id="O2" value="0.063" lower_limit="0.045" upper_limit="0.090"/>
                    <measurement group_id="O3" value="0.075" lower_limit="0.050" upper_limit="0.111"/>
                    <measurement group_id="O4" value="0.063" lower_limit="0.045" upper_limit="0.090"/>
                    <measurement group_id="O5" value="0.078" lower_limit="0.054" upper_limit="0.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C Month 5 (N= 67; 71; 72; 65; 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.518" lower_limit="2.748" upper_limit="4.504"/>
                    <measurement group_id="O2" value="2.969" lower_limit="2.464" upper_limit="3.578"/>
                    <measurement group_id="O3" value="2.936" lower_limit="2.440" upper_limit="3.533"/>
                    <measurement group_id="O4" value="0.029" lower_limit="0.025" upper_limit="0.035"/>
                    <measurement group_id="O5" value="3.326" lower_limit="2.557" upper_limit="4.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C Month 10 (N= 48; 52; 51; 53; 46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.775" lower_limit="0.601" upper_limit="1.000"/>
                    <measurement group_id="O2" value="0.742" lower_limit="0.607" upper_limit="0.907"/>
                    <measurement group_id="O3" value="0.708" lower_limit="0.577" upper_limit="0.867"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O5" value="0.668" lower_limit="0.503" upper_limit="0.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F Day 0 (N= 42; 42; 36; 50; 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.124" lower_limit="0.076" upper_limit="0.202"/>
                    <measurement group_id="O2" value="0.126" lower_limit="0.083" upper_limit="0.190"/>
                    <measurement group_id="O3" value="0.129" lower_limit="0.080" upper_limit="0.206"/>
                    <measurement group_id="O4" value="0.135" lower_limit="0.092" upper_limit="0.198"/>
                    <measurement group_id="O5" value="0.115" lower_limit="0.073" upper_limit="0.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F Month 5 (N= 65; 67; 66; 56; 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.303" lower_limit="1.889" upper_limit="2.806"/>
                    <measurement group_id="O2" value="1.846" lower_limit="1.444" upper_limit="2.360"/>
                    <measurement group_id="O3" value="2.061" lower_limit="1.719" upper_limit="2.472"/>
                    <measurement group_id="O4" value="0.030" lower_limit="0.026" upper_limit="0.035"/>
                    <measurement group_id="O5" value="1.881" lower_limit="1.508" upper_limit="2.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F Month 10 (N= 73; 71; 65; 77; 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.413" lower_limit="0.320" upper_limit="0.532"/>
                    <measurement group_id="O2" value="0.335" lower_limit="0.252" upper_limit="0.443"/>
                    <measurement group_id="O3" value="0.397" lower_limit="0.307" upper_limit="0.512"/>
                    <measurement group_id="O4" value="0.042" lower_limit="0.031" upper_limit="0.056"/>
                    <measurement group_id="O5" value="0.339" lower_limit="0.252" upper_limit="0.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F Day 0 (N= 41; 43; 38; 48; 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" lower_limit="0.038" upper_limit="0.075"/>
                    <measurement group_id="O2" value="0.045" lower_limit="0.033" upper_limit="0.062"/>
                    <measurement group_id="O3" value="0.062" lower_limit="0.040" upper_limit="0.096"/>
                    <measurement group_id="O4" value="0.060" lower_limit="0.041" upper_limit="0.086"/>
                    <measurement group_id="O5" value="0.065" lower_limit="0.044" upper_limit="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F Month 5 (N= 66; 68; 70; 59; 66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.581" lower_limit="1.970" upper_limit="3.381"/>
                    <measurement group_id="O2" value="2.112" lower_limit="1.544" upper_limit="2.891"/>
                    <measurement group_id="O3" value="2.098" lower_limit="1.551" upper_limit="2.838"/>
                    <measurement group_id="O4" value="0.027" lower_limit="0.025" upper_limit="0.029"/>
                    <measurement group_id="O5" value="1.988" lower_limit="1.426" upper_limit="2.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F Month 10 (N= 73; 69; 63; 75; 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.783" lower_limit="0.595" upper_limit="1.032"/>
                    <measurement group_id="O2" value="0.642" lower_limit="0.474" upper_limit="0.870"/>
                    <measurement group_id="O3" value="0.644" lower_limit="0.469" upper_limit="0.885"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O5" value="0.578" lower_limit="0.426" upper_limit="0.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms During the Primary Vaccination Course</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, irritability, loss of appetite and fever (rectal temperature greater than or equal to 38 degrees Celcius).</description>
        <time_frame>During the 8-Day (Day 0-7) follow-up period after any vaccine dose during the primary vaccination course</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, on subjects having completed the symptom sheet.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and General Symptoms During the Primary Vaccination Course</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, irritability, loss of appetite and fever (rectal temperature greater than or equal to 38 degrees Celcius).</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, on subjects having completed the symptom sheet.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="47"/>
                    <measurement group_id="O5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms After Administration of the Polysaccharide Challenge Dose</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, irritability, loss of appetite and fever (rectal temperature greater than or equal to 38 degrees Celcius).</description>
        <time_frame>During the 8-Day (Day 0-7) follow-up period after the polysaccharide challenge dose</time_frame>
        <population>The analysis was performed on the Booster Total Vaccinated Cohort, on subjects having completed the symptom sheet.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and General Symptoms After Administration of the Polysaccharide Challenge Dose</title>
          <description>Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, irritability, loss of appetite and fever (rectal temperature greater than or equal to 38 degrees Celcius).</description>
          <population>The analysis was performed on the Booster Total Vaccinated Cohort, on subjects having completed the symptom sheet.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events During the Primary Vaccination Course</title>
        <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 31-Day (Day 0-30) follow-up period after any vaccine dose during the primary vaccination course</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events During the Primary Vaccination Course</title>
          <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Administration of the Polysaccharide Challenge Dose</title>
        <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 31-Day (Day 0-30) follow-up period after administration of the polysaccharide challenge dose</time_frame>
        <population>The analysis was performed on the Booster Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events After Administration of the Polysaccharide Challenge Dose</title>
          <description>Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The analysis was performed on the Booster Total Vaccinated Cohort.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events During the Primary Vaccination Course</title>
        <description>Serious adverse events cover all medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Up to one month after the 3-dose primary vaccination course (Month 5)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events During the Primary Vaccination Course</title>
          <description>Serious adverse events cover all medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events After Administration of the Polysaccharide Challenge Dose</title>
        <description>Serious adverse events cover all medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Up to one month following administration of the polysaccharide challenge dose (Month 11)</time_frame>
        <population>The analysis was performed on the Booster Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>MenHibrix Formulation 1 Group</title>
            <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O2">
            <title>MenHibrix Formulation 2 Group</title>
            <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O3">
            <title>MenHibrix Formulation 3 Group</title>
            <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Menjugate Group</title>
            <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
          <group group_id="O5">
            <title>ActHIB Group</title>
            <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events After Administration of the Polysaccharide Challenge Dose</title>
          <description>Serious adverse events cover all medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on the Booster Total Vaccinated Cohort.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="81"/>
                <count group_id="O5" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: Up to 1 month following primary vaccination and challenge dose; Non-systematically assessed other AEs: Up to 31 days following primary vaccination and challenge dose; Systematically assessed other AEs: During 8-day follow-up after each dose.</time_frame>
      <desc>The number at risk for systematically assessed symptoms comprises only those subjects who had returned the symptom sheet.</desc>
      <group_list>
        <group group_id="E1">
          <title>MenHibrix Formulation 1 Group</title>
          <description>Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="E2">
          <title>MenHibrix Formulation 2 Group</title>
          <description>Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="E3">
          <title>MenHibrix Formulation 3 Group</title>
          <description>Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="E4">
          <title>Menjugate Group</title>
          <description>Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
        <group group_id="E5">
          <title>ActHIB Group</title>
          <description>Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematemesis</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Milk allergy</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Sudden infant death syndrome</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="80" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="60" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="79"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="67" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="80" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pain at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Redness at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Swelling at the injection site</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Rhinorhea</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>Following challenge dose administration</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <description>Following primary vaccination</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

